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Purpose: This study retrospectively evaluated the efficacy and safety of the 6F Angio-Seal (St. Jude Medical, St. Paul,
Minn) as a closure device for transbrachial artery access for endovascular procedures in diabetic patients with critical limb
ischemia.
Methods: From January 2005 and September 2007, 1887 diabetic patients underwent interventional procedures in the
lower limbs at a two diabetic foot centers. Patients presented with rest pain (16%), ulcers (80%), or gangrene (4%).
Systemic anticoagulation with sodium heparin (70 IU/kg) was obtained for all patients at the beginning of the
endovascular treatment. A total of 249 brachial arteries (238 patients) were evaluated for possible Angio-Seal use after
endovascular recanalization of the leg. Color Doppler ultrasound imaging of the artery was obtained before revascular-
ization only in patients with previous Angio-Seal placement in the brachial artery. No further imaging studies were done
in the remaining brachial arteries where the Angio-Seal was deployed at the operator’s discretion. Impairment or
disappearance of the radial pulse or onsets of hand ischemia or hand pain, or impairment of hand function during or at
the end of the endovascular revascularization were all regarded as contraindications to Angio-Seal usage. Evidence of a
highly calcified plaque of the brachial artery access site at the time of vessel puncture was regarded as an absolute
contraindication to the Angio-Seal use. Patients were seen before discharge, at 1, 3, and 8 weeks after the procedure, and
at 3-month intervals thereafter. Complications included hemorrhage, pseudoaneurysm, infection, and vessel occlusion.
Results: A total of 1947 Angio-Seal collagen plugs were deployed in 1709 diabetic patients (90.5%). The Angio-Seal was
used for brachial artery closure in 159 patients (8.4%) in 161 procedures (159 in the left, 2 in the right brachial artery).
In 79 patients (4.2%) in 88 procedures (87 in the left and 1 in the right brachial artery), the device was deemed
contraindicated due to small vessel size in 73 patients (92.4%) or presence of calcium at the access site in five patients
(6.3%). One patient (1.3%) refused the collagen plug closure after revascularization. The non-Angio-Seal group was
evaluated for comparison. The success rate for achieving hemostasis in the Angio-Seal group was 96.9%. Five major
complications (3.1%) at 30 days consisted of two puncture site hematomas >4 cm, two brachial artery occlusions, and one
brachial artery pseudoaneurysm, with three patients requiring open surgery. Minor complications (7.50%) were three
puncture site hematomas < 4 cm, three oozing of blood from the access site, and six patients had mild pain in the cubital
fossa. No further complications were recorded in the 14-month follow-up (range 1-25 months) of a total of 140 patients.
Conclusions: This retrospective study shows that the 6F Angio-Seal is a valuable and safe vascular closure device for
transbrachial access in diabetic patients undergoing interventional procedures for critical limb ischemia. ( J Vasc Surg
2008;47:782-8.)Percutaneous access to the arterial system for endovas-
cular procedures in the lower limbs is usually achieved
through the femoral arteries. When femoral access is pre-
cluded, the brachial or axillary artery can serve as alterna-
tives.1,2 The brachial approach is currently regarded as one
of the most valuable alternatives to transfemoral arterial
puncture.3 In selected cases, this option can also be more
advantageous than the standard approach in terms of acces-
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782sibility of the artery or when the procedure is conducted in
an outpatient setting, or both.2
For several years, manual compression was the only
method of achieving hemostasis of the punctured artery
after diagnostic studies and interventional procedures. Ac-
cess site complications with this technique have been re-
ported to be 6% in most studies and have included
bleeding, pseudoaneurysm formation, and vessel occlu-
sion.4,5 However, the increase in the artery hole diameter
because of the sheath, the time delay until the activated
clotting time (ACT) allows the physician to withdraw the
introducer sheath, and the traditional manual compression
involve prolonged arm mobilization and protracted, some-
times painful, local strong pressure as well as decreased
patient compliance and satisfaction.
These problems have led to a great deal of interest in
alternative methods of achieving hemostasis at the site of
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who have received heavy anticoagulation.6 The earliest
reports describing the use of arterial puncture closure de-
vices were published in 1992 and 1993.7,8 Numerous
reports describing the use of closure devices in the femoral
artery have been published in last 10 years.6,9-13 Con-
versely, few studies on the use of closure devices for the
brachial artery access have been published so far; currently,
there is evidence of only one study with 50 patients in
whom anAngio-Seal (St. JudeMedical, St. Paul,Minn) was
inserted for brachial artery closure after diagnostic or ther-
apeutic interventions.14,15 The purpose of this study was to
assess the feasibility and clinical usefulness of Angio-Seal, a
combined suture and collagen-based device, after brachial
artery retrograde puncture for peripheral arterial interven-
tions in diabetic patients with critical limb ischemia who
have received full anticoagulation therapy.
METHODS
This was a retrospective, single-center study conducted
between January 2005 and September 2007 at Multi-
medica Istituto di Ricovero e Cura a Carattere Scientifico
(IRCCS), Sesto San Giovanni Milan-Santa Maria Castel-
lanza (VA), Italy, in a cohort of diabetic patients who
underwent interventional procedures for critical limb isch-
emia (CLI). The patients presented with rest pain (16%),
ulcers (80%), or gangrene (4%). No patients with claudica-
tion were included in this study.
Patients were assessed for the presence of CLI as de-
fined by the Transatlantic InterSociety Consensus (TASC)
criteria.16 Critical limb ischemia was diagnosed if one foot
pulse was reduced or absent, if ankle pressure was70 mm
Hg when assessable, and if transcutaneous oxygen tension
at the dorsum of the foot was 50 mm Hg. Examination
with duplex ultrasound (DUS) imaging and angiography
were performed in all patients with these abnormalities. If
obstruction 50% of the vessel diameter was present, per-
cutaneous transluminal angioplasty (PTA) was performed
as a first-choice revascularization procedure in the same
angiographic session.17
A total of 249 brachial arteries in 238 patients were
evaluated for possible Angio-Seal use after endovascular
recanalization of the lower limbs. The brachial access was
selected in cases of difficult femoral access due to severe
groin fibrosis, local vascular surgery, aortic-iliac bifurcation
being too acute, obesity, or an absent femoral pulse. All
brachial access procedures were performed at the antecubi-
tal fossa. Patient age, sex, demographics, and the use of
anticoagulants and antiplatelet agents were recorded.
Procedure. The same team of operators (J. C., T. L.)
did all interventional procedures and Angio-Seal deploy-
ments. All operators had used the Angio-Seal device at least
150 times in the femoral artery before 2005, and therefore,
no learning curve with the device was involved in the
present study. Patients received 100 mg of aspirin (Bayer,
Leverkusen, Germany) orally 2 hours before the scheduled
intervention and continued taking it indefinitely.All procedures were performed in the angiography
suite after informed consent was obtained. After subcuta-
neous injection of a small amount of lidocaine, brachial
artery cannulation was achieved with 21-gauge entry nee-
dles using the Seldinger technique. Procedures were not
performed in patients who were taking warfarin if their
international normalized ratio was 2.0. The size of the
vascular sheath used, the type of procedure performed, and
the indication for arteriography were noted. Previous diag-
nostic angiography was done through the brachial ap-
proach using a 5F, 25-cm-long introducer sheath (Super
Sheath, Boston Scientific, Natick, Mass) in all patients.
When indication to iliac, femoral, or popliteal endovascular
treatment was made, the 5F sheath was changed for a 6F,
90-cm-long armored introducer sheath (Accuflex, Bipore
Inc, Northvale, NJ).
All patients undergoing interventional treatments re-
ceived 5000 IU of heparin after insertion of the 6F intro-
ducer sheath. Additional heparin was administered during
the procedure to maintain an ACT 250 seconds. Eptifi-
batide (Integrilin, Millennium Pharmaceuticals Inc, Cam-
bridge, Mass), an antagonist of platelet glycoprotein IIb-
IIIa, was administered in three patients after sudden
thrombosis of the lower limb vessels occurring during
revascularization.
Sheath removal and device placement was performed
immediately after completion of the angioplasty. No Angio-
Seal device was implanted in patients in whom the interven-
tional treatment was deemed not possible or contraindi-
cated after angiography from the brachial approach. These
patients underwent manual compression of the 5F hole in
the artery. Heparin was never reversed at the conclusion of
the angiography or endovascular intervention. Periproce-
dural antibiotics were not used.
In all cases, a 6F, 90-cm-long, armored sheath was used
for the interventional procedure. No 5F sheaths were used
for interventional procedures performed from the brachial
artery in the present study. Color Doppler US imaging of
the brachial artery was done before Angio-Seal deployment
in the first 15 patients of the study. No imaging studies
were done in the remaining brachial arteries where the
Angio-Seal was deployed at the operator’s discretion;
therefore, in almost all patients, the decision to deploy an
Angio-Seal in the brachial artery was made on clinical
criteria solely. Specifically, impairment or disappearance of
the radial pulse, or onsets of hand ischemia, hand pain, or
impairment of hand function during or at the end of the
procedure were considered contraindications to Angio-Seal
use. Indeed, the occurrence of any of these symptoms
might indicate the presence of a vessel diameter 4 mm at
the puncture site.
No difficulty was encountered in placing the collagen
of the Angio-Seal in the superficial location of the brachial
artery provided it was 1 cm. In fact, a further contraindi-
cation to the procedure was the evidence of a superficial
brachial artery sited to 1 cm beneath the skin of the
antecubital fossa. For this reason, the Angio-Seal was de-
ployed in each case by the same operator who had previ-
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aware of the real depth of the brachial artery. The evidence
of a highly calcified plaque of the brachial artery access site
at the time of vessel puncture was regarded as the main
contraindication to the Angio-Seal use.
Manual compression or Angio-Seal deployment was
done immediately after the conclusion of each procedure.
After Angio-Seal placement, manual compression was ap-
plied for 45 to 60 second to all patients. At the end of
Angio-Seal placement or manual compression, the access
site was screened for 5 minutes. Then a compression ban-
dage was placed over the puncture site in all patients and
they were placed at bedrest for 2 hours. No Angio-Seal
devices were employed in an outpatient setting. A 6F
Angio-Seal device was deployed after the use of a 6F sheath.
No 8F Angio-Seal or other types of closure devices were
used in the present study.
Follow-up. The radial pulse was monitored immedi-
ately after closure device deployment as well as at 15 and 30
minutes and at 2-hour intervals thereafter. Time to removal
of the cubital fossa compression bandage was 16 to 24
hours. The day after the percutaneous intervention, all
patients underwent clinical follow-up examinations that
included a physical examination performed by an interven-
tional radiologist (J. C., T. L.) vascular surgeons (L.S.,
C.A.) or a diabetologist (M.D.P., F.E., C.G.) and a deter-
mination of brachial, radial, and ulnar pulses of the punc-
tured arm. Patients were also examined for access site
complications and success of the intervention before dis-
charge from the hospital, at 1, 4, and 12 weeks after the
procedure, and at 3-month intervals thereafter. Complica-
tions were classified according to severity and recorded as
described in Table I. When a hematoma occurred, this was
marked using a permanent ink marker and measured to
quantify its size.
Study end points and definitions. The primary end
point was the combined number of major complications at
30 days after the endovascular treatment. Procedural suc-
cess was measured as an additional primary end point and
was defined a hemostasis achieved with the collagen plug
device, followed by compressive bandage for 16 hours.
Failure to deploy the device, regardless of whether the
outcome was final hemostasis or a complication, was de-
Table I. Vascular access closure after endovascular revascu
Variable Total, No. (%)
Femoral ar
No (%)
Patients treated for CLI 1887
Angio-Seal 1709 (90.5) 1480 (78
Manual compression 178 (9.5) 90 (4.7
Overall cases performed for CLI 2160
Angio-seal placement 1947 (90.1) 1715 (79
Manual compression 213 (9.9) 116 (5.4
CLI, Critical limb ischemia.fined as the inability to gain access with the device sheath,to engage the artery with the anchor, or to successfully
secure the anchor or the collagen plug. The secondary end
point was the combined number of minor complications
during the first 30 days after the vascular closure procedure.
RESULTS
During the study period, 2160 endovascular proce-
dures were performed, and 1947 Angio-Seal collagen plugs
were deployed in 1709 of 1887 diabetic patients (90.5%)
treated by endovascular recanalization for CLI. The Angio-
Seal was used for brachial artery closure in 159 patients
(8.4%) in 161 procedures (159 in the left, 2 in the right
brachial artery); whereas in the remaining 79 patients
(4.2%), consisting of 88 procedures (87 in the left and 1 in
the right brachial artery), the device was contraindicated
owing to the onset of hand pain or ischemia or both in 73
patients (92.4%) or the presence of calcium at the access site
in five (6.3%). One patient (1.3%) refused to undergo
collagen plug closure after revascularization. Two patients
underwent repeat 6 F Angio-Seal deployments in the same
left brachial artery at 2 and 16 months from the first
intervention, respectively. An additional puncture of the
femoral artery (4 retrograde, 15 antegrade) was required in
the same operative session in 19 patients, all of whom
underwent 6F Angio-Seal device deployments at the end of
the procedure; therefore, 180 6F Angio-Seal plugs were
used in this cohort of patients (Angio-Seal group).
The 79 patients in whom the Angio-Seal plug was not
inserted (non-Angio-Seal group) were evaluated for com-
parison (Table I). The non-Angio-Seal group included 54
women and 25 men with age, comorbidities, and vascular
lesions of the lower limbs that were comparable with those
of the Angio-Seal group.
The Angio-Seal group included 58 women and 101
men, and their mean age was 75 years (range, 36-97). All
patients had diabetes, 54% had hypertension, and 61% had
coronary artery disease. Antiplatelet agents were being
taken by 79% of patients, and 21% were receiving warfarin
or Coumadin (Bristol-Myers Squibb, Princeton, NJ) anti-
coagulation. The 161 interventions were performed on 22
iliac arteries, 28 common femoral arteries, 71 superficial
femoral arteries, 16 profunda arteries, and 24 popliteal
arteries. Angioplasty was followed by stenting in 157 pa-
ation for critical limb ischemia
Brachial artery,
No (%)
Brachial and femoral
artery, No (%)
Bilateral femoral
artery, No (%)
159 (8.4) 19 (1) 51 (2.7)
79 (4.2) 5 (0.2) 4 (0.2)
161 (7.4) 19 (0.9) 52 (2.4)
88 (4.1) 5 (0.2) 4 (0.2)lariz
tery,
.4)
)
.4)
)tients, and direct stenting was done in two patients. Stent
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ically significant lesions of the iliac artery as well as in
patients who had a residual stenosis50% after angioplasty
of the femoral-popliteal artery.
Primary end points. Five (3.1%) major complications
were recorded in the Angio-Seal group: two left brachial
artery occlusions (1.25%), one 5-cm pseudoaneurysm
(0.65%), and two puncture site hematomas (1.25%) of 4.5
and 5 cm, respectively. One brachial occlusion was caused
by a collagen plug displacement within the vessel lumen
(with immediate occlusion of the artery as a result), and
another was due to a brachial artery intimal dissection;
specifically, this was caused by the anchor lifting up an
intimal plaque that resulted in vessel thrombosis and isch-
emic rest pain at 27 days. Both patients were successfully
treated by open surgery24 hours of diagnosis. The 5-cm
pseudoaneurysm developed after 2 hours from an appar-
ently successful closure procedure. It was due to failure of
the anchor to engage the arterial wall as the Angio-Seal
delivery system was withdrawn before being properly posi-
tioned. The patient underwent successful surgical repair of
the lesion the day after the interventional procedure. Fi-
nally, the two puncture site hematomas developed despite
an initially successful deployment of the device, one at 30
minutes, and one at 3 hours. In both cases, no surgical
treatment of the hematoma was needed.
The rate of major complications at 30 days was 3.1%.
Of importance was that three of these five major complica-
tions occurred during the first 50 cases. Procedural success
for obtaining hemostasis was achieved in 156 of the 161
cases (96.9%), because in addition to the three patients who
required open surgery, in two patients there was failure to
deploy the device. In these instances, antecubital fossa
hemostasis was achieved by manual compression.
Four (4.6%) major complications were recorded in the
non-Angio-Seal group after manual compression: one bra-
chial artery thrombosis (1.1%) and three puncture site
hematomas (3.4%)4 cm. All complications developed4
hours of the procedure. The brachial thrombosis required
immediate surgical repair. One patient with a hematoma
received a blood transfusion.
Secondary end points. Minor complications were re-
corded in 12 patients (7.45%) in the Angio-Seal group:
three (1.86%) had oozing of blood from the puncture site
at 25, 45, and 150 minutes, respectively, requiring manual
compression, and three (2.48%) had hematomas 4 cm.
Furthermore, six patients (3.72%) experienced mild pain at
the puncture site during the first 24 hours after the proce-
dure. The overall rate of complications in the Angio-Seal
group at 30 days was 10.5%.
Eight (6.8%) minor complications were recorded in the
non-Angio-Seal group. One arteriovenous fistula (1.1%)
developed; two patients (2.3%) had oozing of blood from
the puncture site requiring further manual compression at
20 and 60 minutes; and two hematomas (2.3%) 4 cm
occurred. Two patients (2.3%) experienced severe pain at
the puncture site during the first 12 hours after the proce-
dure requiring the continuous administration of intrave-nous analgesic drugs. The overall rate of complications in
the non-Angio-Seal group at 30 days was 13.7%. No elbow
infection was seen in either group at any time. Major and
minor complications are reported in Table II.
All but two patients in the Angio-Seal group were sent
home with a normal radial pulse. A mild impairment of the
left radial pulse that was noted at discharge in one patient
resolved completely after 8 weeks. The impairment in the
remaining patient was due to an underlying left subclavian
artery stenosis that was successfully treated endovascularly
after 6 weeks. No Angio-Seal or manual compression-
related complications were seen at the 14-month follow-up
(range, 1-25 months).
During this time, 16 patients in the Angio-Seal group
died of unrelated causes. An additional three patients were
lost to follow up 6, 9, and 11 months after their procedure
and were doing well at the time of their last visit. No
immediate or late complications were seen in patients in
whom the Angio-Seal was used also in the groin. Six
patients in the non-Angio-Seal group died of unrelated
cause during the follow-up period, whereas two patients
were lost to follow-up 10 and 12 months after the proce-
dure. The difference in rates of major and minor complica-
tions between the two groups was not statistically different.
DISCUSSION
In cases of severe iliac occlusive disease, the axillary and
brachial artery access routes have been used as alternative
approaches to the femoral artery.5,18 The brachial approach
is currently regarded as the most useful alternative to trans-
femoral arterial puncture, and its use, particularly for inter-
ventions in the iliac axis, is increasing among endovascular
therapists.3 This option can also be more advantageous in
selected cases than the standard approach in terms of acces-
sibility of the artery or when the procedure is conducted in
Table II. Complications after brachial artery puncture
observed at 30 days in patients with and without Angio-
Seal
Complication
Angio-Seal
group
(n  161),
No (%)
Non-Angio-Seal
group
(n  88),
No (%)
Major complication 5 (3.3) 4 (4.5)
Hematoma 4 cm in diameter
or bleeding requiring
transfusion
2 (1.3) 3 (3.4)
Pseudoaneurysm 1 (0.7) 0
Vessel occlusion or thrombosis 2 (1.3) 1 (1.1)
Minor complications 12 (7.5) 7 (8.0)
Hematoma 4 cm or bleeding
not requiring transfusion
3 (1.9) 2 (2.3)
Oozing of blood 3 (1.9) 2 (2.3)
Arteriovenous fistula 0 1 (1.1)
Pain at the puncture site (up
to24 h)
6 (3.7) 2 (2.3)
Overall complications 17 (10.8) 12 (12.5)an outpatient setting, or both.2
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characterized by distal, multiple obstructions with a
higher percentage of occlusions with respect to steno-
ses.19 Stenosis or occlusions of the iliac and common
femoral axis are not uncommon, however, and may
render the femoral approach very challenging. The obe-
sity present in some diabetic patients may not allow the
antegrade puncture, whereas other diabetic patients have
undergone previous surgery at the groin, which may
contraindicate the use of the transfemoral approach.
Finally, some patients, particularly elderly ones, show a
very angulated aortic bifurcation and thus require a
different approach from the femoral one. In all these
situations the choice of the brachial artery as vascular
access has been proven to be relatively safe and effective.3
On the other hand, such an approach does not generally
facilitate the use of devices larger than 7F.
Manual compression is the accepted method of achiev-
ing hemostasis after brachial artery access for diagnostic and
interventional procedures. A variety of arterial closure de-
vices have been introduced with the aim of reducing the
time to hemostasis, but all are indicated for femoral use
only. Closure devices show several advantages compared
with manual compression. First, they are especially effective
for highly anticoagulated patients and patients on glycop-
rotein IIb/IIIa inhibitors. Second, closure devices allow
early ambulation and provide a high level of patient satis-
faction. Finally, their use can dramatically enhance the
overall cost-effectiveness and productivity of vascular sur-
gery departments and catheter laboratories, particularly of
those that perform several endovascular procedures per
day.9,20
The disadvantage is the presence of the intravascular
suture and anchor, which can act as a nidus for platelet
aggregation, the risk of intravascular deployment of the
collagen plug with subsequent occlusion of the accessed
artery, and risk of distal embolization of the anchor. The
latter, emphasizes the need to ensure that the vascular
surgeons are aware of the presence of the anchor in patients
in whom a further surgical procedure is needed so that the
retaining suture is not cut.21
The recent growth in the number and design of closure
devices has occurredwithout a consensus aboutwhether these
devices should be used routinely or selectively and under what
circumstances they should be used.11 Moreover, a variety of
clinical trials and observational studies show conflicting re-
sults, with some showing superiority, inferiority, and no dif-
ference when vascular closure devices are compared with
manual compression.22,23
The Angio-Seal device was introduced in Europe in
1994. The original design has undergone several modifica-
tions that allow for easier and more consistent deployment.
Retrograde closures of the brachial arteries have not yet
been approved by the United States Food and Drug Ad-
ministration. The device consists of a small lozenge-shaped
anchor composed of a polylactide and polyglycolide poly-
mer, a collagen plug, and suture contained within a special
carrier system.12 When inserted, the arterial wall and punc-ture site are “sandwiched” between the anchor (within the
vessel lumen) and the plug (on the adventitia) by traction
on the suture and by pushing on a small plastic tube that is
also threaded over the suture to provide countertraction.
The Angio-Seal is an extremely simple device to master, it
can be consistently deployed within 45 to 90 seconds, and
it is completely bioabsorbable. Vessels previously sealed
with this device have been safely re-entered within 1 to 7
days.24
With increased usage of these devices, reports of
complications have also emerged. Common femoral ar-
tery occlusion secondary to the use of the Angio-Seal has
been reported.25 One of the most important complica-
tions has been collagen embolization to the lower ex-
tremity arteries.26,27 Particular concern has also been ex-
pressed about infections resulting from the placement of
these devices.28,29
In our experience, the Angio-Seal for brachial artery
puncture site closure is a safe technique with an acceptable
rate of complications. Although the use of Angio-Seal in
the brachial artery in our cohort of diabetic subjects did not
decrease the time of armmobilization compared with man-
ual compression, patient compliance and satisfaction was
high owing to the reduced local compression at the site of
puncture and a faster return to the ward. The rate of major
complications in the present study was as low as 3.1%, with
open surgery being required only in 1.90% (3 patients), and
compared well with that of manual compression. Of impor-
tance was that all but one patient in the Angio-Seal group
did very well after discharge. The only patient requiring
unintended readmission to the hospital 30 days of a
procedure was the patient with brachial artery dissection
that evolved into vessel thrombosis 3 weeks after the inter-
vention.
These results compare well with results from other
studies conducted using the Angio-Seal or a different clo-
sure device in the femoral artery; however, great care has to
be taken in certain patients, particularly youngwomen.12,13
Indeed, women generally have smaller brachial arteries than
men, and young patients are more prone to vessel spasm
during and also after vessel catheterization. To avoid
Angio-Seal–related complications, the brachial artery inner
diameter should be 4 mm. For this reason, the brachial
artery at the antecubital fossa should be carefully evaluated,
whenever possible, by color Doppler US imaging before
Angio-Seal deployment. When color Doppler US is not
available, clinical evaluation of the hand throughout the
procedure is mandatory. Evidence of hand pain or ischemia
at any time during the procedure increases the risk of
complications after Angio-Seal placement. Manual com-
pression should be preferred in these situations.
Great care should be also taken in patients whose
brachial artery is too superficial in location, thus presenting
inadequate space for the collagen plug. To overcome this
problem, some authors15 suggest the use of a local anaes-
thetic solution to be infiltrated both in the skin and subcu-
taneous tissue surrounding the puncture site before Angio-
Seal deployment.15 According to these authors, a local
JOURNAL OF VASCULAR SURGERY
Volume 47, Number 4 Lupattelli et al 787tissue infiltration of 5 mL of solution in the region of the
entry site may easily result in a tissue bulk of 2 to 2.5 cm3,
which creates enough room for safe anchor placement and
collagen sponge deployment. Although manual compres-
sion may not be necessary in most patients, we recommend
this maneuver for at least 45 to 60 seconds after complete
deployment of the device.
In the present series, no color Doppler US imaging of
the brachial artery was performed before vessel puncture,
which is a main limitation of this study. Indeed, the deci-
sion to use the closure device was made solely on clinical
criteria, as reported in “Material and Methods.” Actually, a
pre-evaluation of the brachial artery with color Doppler US
imaging is likely to reduce the rate of complications at the
site of puncture. In a recent article by Belenky et al,15 the
technical success of Angio-Seal deployment in the brachial
artery previously evaluated with color Doppler US was as
high as 100%.Moreover, these authors reported no related-
device major complications in the short- and mid-term
follow-up of 65 patients after Angio-Seal deployment in the
brachial artery for diagnostic or therapeutic angiographies.
CONCLUSION
This retrospective study shows that the 6F Angio-Seal
is a valuable and safe vascular closure device for transbra-
chial access in diabetic patients undergoing interventional
procedures for CLI. Preintervention color-Doppler US
imaging of the brachial artery is not mandatory but may
increase the feasibility and safety of the procedure by pro-
viding better patient selection. Further studies in larger
patient groups and with use of different closure devices are
needed to determine the role of closure devices in brachial
artery access.
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RECOUP THE LOUPES 
Despite extremely limited resources, surgeons in developing countries work to provide their 
patients with the best possible care. For many of these surgeons, technology such as loupes, 
which facilitate delicate procedures, is simply out of reach.  
One year ago, Loupes Around The World distributed its first pair of loupes to a plastic surgeon
in Phnom Penh, Cambodia. Before Loupes Around The World, this surgeon commonly 
repaired cleft lips and palates, and treated trauma patients with maxillofacial injuries without 
the benefit of surgical magnification. Since then, this not-for-profit organization has provided 
loupes to surgeons from Panama to India and continues to receive requests from surgeons 
around the world.  
Loupes Around The World is now recycling donated loupes via a program called “Recoup the 
Loupes.” Surgeons with unused loupes are asked to send them to the foundation; there, repairs 
can be made to adjustable loupes, and the telescopes from fixed loupes can be installed into 
new lenses and frames. For fixed loupes, optical measurements are taken to ensure that the 
loupes will meet the needs of each individual surgeon. 
Please send your unused loupes to:  
David C. Knight, M.D., F.A.C.S. 
Loupes Around The World 
c/o Surgical Associates of Waterbury 
1211 West Main St. 
Waterbury, CT 06708 
Loupes Around The World accepts loupes made by any manufacturer. For more information 
about Loupes Around The World, as well as information about how to contribute, please visit: 
www.loupesaroundtheworld.org. Upon receiving loupes, a letter of acknowledgment will be 
sent to the donor for tax purposes. Loupes Around the World is a 501(c)3 tax-exempt 
organization.  
